Skip to content
DataLookout
Menu

RH-PLNCT05936333

Exploration of Allograft Humoral Rejection in Chronic Histiocytic Intervillositis

StatusUnknown
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Jan 2025 to Oct 11, 2025
    • Start date changed from estimate of Jul 2023 to Oct 11, 2023
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of patients diagnosed with CHI, defined by the concomitant presence of the 3 criteria required to evoke humoral alloimmune rejection for this pathology
Timeframe: up to 6 months

Secondary (6)

To measure the FSA levels by Mean Fluorescence Intensity for the different obstetrical complications: intrauterine growth retardation (IUGR), fetal death in utero and abortion for IUGR.
to measure the correlation between fetus-specific antibody level by Mean Fluorescence Intensity and the severity and/or precocity of obstetrical complications
measure of semi-quantitative graduation of C4d in placenta compared to percentage of villositis
measure of semi-quantitative graduation of CD68+ infiltrate in placenta compared to surface and number of involved villositis
To measure the expression of HLA class I and II molecules by placental villi by ß2-microglobulin and HLA-DR labelling
Show 1 moreShow less
Epitope analysis with algorithm developped by laboratoire HLA de St Louis (Pr JL Taupin)

Arms and interventions

Patient with chronic histiocytic intervillositisExperimental

Patient with CHI, as well as her children and their father. Blood collection from the parents, saliva collection (or blood collection) from the children, placenta collection

patients with anti-phospholipid syndromes (APS)Active comparator

Patient with antiphospholipid syndrome, as well as her children and their father. Blood collection from the parents, saliva collection (or blood collection) from the children, placenta collection

women with a third full-term pregnancy without growth retardation.Placebo comparator

Patient with normal pregnancies, as well as her children and their father. Blood collection from the parents, saliva collection (or blood collection) from the children, placenta collection

Procedures: Biological collection

Sites

1 site in 1 country

  • Antoine Béclère HospitalClamart, France